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Available online 24 February 2013Abstract The repair of skeletal defects remains a substantial economic and biomedical burden. The extra-embryonic
fetal stem cells derived from amniotic fluid (AFSCs) have been used for the treatment of large bone defects, but
mechanisms of repair are not clear. Here we studied the potential contribution of human AFSCs to the modeling of an
ectopic bone.
We found that AFSCs are not osteogenic in vivo, and, compared to bone marrow-derived stromal cells, recruit more host
CD31 and VEGF-R2 positive cells. Finally, when AFSCs were co-implanted with human-bone forming cells, a
normo-osteosynthesis occurred, the engineered ossicle was hyper-vascularized, but AFSCs were not retrieved in the
implant within 2 weeks. We concluded that AFSCs do not contribute to the deposition of new bone, but act as a powerful
proinflammatory/proangiogenic boost, driving a host response, ending in AFSC clearance and vascularization of the bone
environment.
In our model, a source of osteocommitted cells, capable to engraft and proliferate in vivo, is needed in order to engineer
bone. The angio-attractant properties of AFSCs could be exploited in strategies of endogenous cell homing to actively
recruit host progenitors into a predefined anatomic location for in situ bone tissue regeneration.
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osteoblasts; BMSC, bone marrow stromal cells.
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Although bone tissue engineering offers a valid alternative to
current bone autograft and allograft surgeries, the repair of
skeletal defects still represents a substantial economic and
biomedical burden (Conrad and Huss, 2005). Tissue engineer-
ing strategies for the replacement of load-bearing tissues
require a combination of a scaffold, a source of bone forming
cells, and growth factors (Langer and Vacanti, 1993). Native
bone forming cells, osteoblasts, are typically difficult to
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cell population with an osteogenic potential would be
preferred. Bone marrow-derived stromal cells (BMSCs, also
known as bone marrow-derived mesenchymal stem cells),
which have been long used for bone tissue engineering
applications, require specialized harvesting and purification
procedures and their presence is also reduced in aged bone
marrow (Caplan, 2004).
Amniotic fluid was described by De Coppi et al. (2007) as
a new source of stem cells, which can be directed into the
three primary embryonic lineages of mesoderm, ectoderm
and definitive endoderm. Amniotic fluid-derived stem cells
(AFSCs) are easily accessible and readily available from
amniocentesis samples that would be otherwise discarded.
AFSCs may approach the plasticity degree of embryonic
stem cells, but their use in regenerative medicine does not
present disadvantages such as ethic controversies, the risk
of teratoma formation and the need of a feeder layer to
grow.
Guldberg's group (Peister et al., 2009) demonstrated the
potential of AFSCs to produce 3D mineralized bioengineered
constructs in vitro and in vivo, suggesting that AFSCs may be
an effective cell source for functional repair of large bone
defects. In particular, it was shown that: i) in vitro
pre-differentiated AFSCs produced more mineralized ma-
trix when implanted subcutaneously (Peister et al., 2009);
ii) in 2D and 3D cultures AFSCs have a delayed but more
robust mineralization rate compared to the BMSCs (Peister
et al., 2011); and iii) AFSC and BMSC-seeded polymer
scaffolds, orthotopically implanted, repair rat critically
sized femoral defects with no significant differences
between the two sources and with significantly higher
bone in-growth compared to acellular scaffolds (Dupont et
al., 2010).
Finally, Rodrigues et al. further pointed out the
concept that the culture environment can pre-commit
AFSCs toward an osteogenic phenotype, and that AFSCs
differentiation stage has a significant impact on the
outcome of the in vivo healing of large bone defects
(Rodrigues et al., 2012).
All together these observations suggest that: i) AFSCs,
although expressing mesenchymal markers, are quite un-
committed compared to adult and more osteogenic-directed
BMSCs; and ii) in spite of their not being osteogenically
committed, AFSC can drive an in vivo bone tissue repair
comparable to bone marrow MSC.
Our group has previously demonstrated that undiffer-
entiated AFSCs, when implanted in vivo, are not retrieved
in the site of implantation, but they play a pivotal role in
mounting a reparative response through the recruitment
of host progenitor cells (Mirabella et al., 2011a). In
particular, the AFSC secretome, which is rich in
chemokines and growth factors, is responsible for a cell
paracrine effect on vessel growth and possibly local niche
activation (Mirabella et al., 2011b, 2012).
The induction of endogenous cell homing; i.e., the
recruitment of host stem cells into a predefined anatomic
location for in situ tissue regeneration, represents an
alternative to the traditional tissue engineering approach.
Biomaterials, cells, drugs, and biological molecules can act as
“navigation cues and signals” stimulating endogenous cell
homing (Chen et al., 2011).Here, using bone forming cells and a ceramic scaffold, we
engineered a microenvironment, which gives rise to bone
tissue after 1–2 months in vivo. We studied how the
presence of human amniotic fluid-derived stem cells
contribute to the in vivo modeling of the formed ectopic
bone and we found that the recruitment of vessels and
inflammatory cells can: i) drive a host's response which
determines AFSC fate, and ii) induces the vascularization of
the engineered bone, without affecting the normal
osteogenesis.Materials and methods
Cell isolation and culture
Human AFSCs were supplied by the Cytogenetic Laboratory of
Galliera Hospital (Genoa, Italy) as normal karyotyped amnio-
centesis samples from twenty 15–17 weeks pregnant women,
after obtaining written informed consent. AFSCs were isolated
as previously described (De Coppi et al., 2007; Mirabella et al.,
2011b; 2012). Briefly, cells were harvested by trypsinization
from confluent back-up human amniocentesis cultures, cKit
immunoselected on a Mini-MACS apparatus (Milteyi Biotec,
Bergisch Gladbach, Germany) and expanded in αMEM medium
(Gibco, Milan, Italy) containing 15% ES cell FBS (Gibco),
2 mM L-glutamine and 100 U penicillin, 100 μg streptomycin
(Gibco), supplemented with 18% Chang B and 2% Chang C
(Irvine Scientific, Santa Ana, CA, USA), at 37 °C within a 5%
CO2 atmosphere. Cultured cells between passage 6 and 10
were tested for the expression of lineage specific surface
molecules in a Cyan ADP Cytofluorimeter (Beckman Coulter)
and the absence of hematopoietic markers together with the
presence of mesenchymal markers was confirmed (Mirabella
et al., 2012; Arnhold et al., 2011). Luciferase-transduced
AFSCs were checked for the same markers and for prolifera-
tion rate and used within passage 10.
Samples of human bone were obtained from six informed
consent-giving patients undergoing hip joint replacement
surgery at the Orthopaedic Surgery Unit of San Martino
Hospital (Genoa, Italy). We report as osteoblasts (OBs) the
heterogeneous population of bone forming cells isolated
from the trabecular bone with a specific protocol (Meikle et
al., 1992) which collects only the collagenase digested
fractions. Briefly, the bone was cut into small pieces
(2 mm × 2 mm), washed in Ringer solution (10 min, 10
times), and then sequentially digested in 1 mg/ml Trypsin
(Gibco, Milan, Italy), 10 min; 2 mg/ml Dispase (Sigma, Milan,
Italy), 20 min; and 800 U/ml Collagenase type 1 (Biochrom,
AG Berlin, Germany), 1 h, 2 times in Ringer solution at 37 °C.
Only cells released by the collagenase digestions were
collected, washed, plated at a density of 10.000 cells/cm2,
and grown to 95% confluence in Iscove's Modified Dulbecco's
Medium (Euroclone, Milan, Italy) supplemented with 10% FBS
(Lonza, Verviers, Belgium), at 37 °C in an humidified atmo-
sphere of 5% CO2; OB were tested for alkaline phosphatase
activity (ALP Detection Kit from Sigma, St. Louis, MO, USA) and
exclusively used at passage 1 or 2. Each time these OB are
ectopically implanted in vivo, they form bone (100% of success
rate) without supporting hematopoiesis. For experiments
requiring cell cycle inactivation, osteoblasts were pretreated
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before implantation in vivo.
2D and 3D osteogenic differentiation
For the differentiation in monolayer (2D), AFSCs were seeded
at a density of 20,000 cells/cm2 and cultured in the
osteogenic medium, previously described (Peister et al.,
2009), consisting of α-MEM supplemented with 17% FBS, 1 μM
of dexamethasone, 6 mM of β-glycerol phosphate, 50 μg/ml
of ascorbic acid 2-phosphate, and 50 ng/ml of thyroxine
(Sigma, Milan, Italy). The medium was changed three times
per week. After 28 days, cells were fixed in PFA 3.7% and
calcium deposits were stained in dark red using 0.4 mM
alizarin red S, pH 4.2 (Sigma, Milan, Italy). Alkaline phospha-
tase activity was assayed following the manufacturer's in-
structions of alkaline phosphatase staining kit (Sigma, St. Luis,
MO, USA).
To assess the osteogenic differentiation in 3D, AFSCs
were seeded onto Skelite® disks (Octane Medical Group,
Kingstone, Canada) at a density of 6 × 105/disk. Skelite disk
(9 mm diameter, 1.2 mm height; 67% Si-TCP and 33% HA =
B-TCP) was chosen as this silicon stabilized tricalcium
phosphate biomaterial presents an interconnected, open
pore structure similar to cancellous bone and has a porosity
level of approximately 60% (Tortelli et al., 2009).
AFSC-Skelite® constructs were placed at the bottom of
wells of 24-well plate coated with 1% of agarose. After 3 h of
incubation at 37 °C to allow adherence of cells, 2 ml of
osteogenic medium was carefully added. Disks were
maintained in culture at 37 °C with 5% CO2. Medium was
changed three times a week. After 28 days in 3D cultures,
constructs were fixed in PFA 3.7% overnight at 4 °C,
decalcified in Osteodec (Bioptica, Milan, Italy) for about
1 week, dehydrated in alcohols, paraffin-embedded and
processed for hematoxylin/eosin staining.
In vivo osteogenesis
In vivo osteogenesis was assayed according to a protocol
previously optimized in our laboratory (Martin et al., 1997).
Briefly, either 1 × 106 OBs or a mix of 1 × 106 OBs and 1 × 106
AFSCs were loaded onto Skelite® cubes (5 × 5 × 5 mm) and
embedded in fibrin glue (TissueColl®, Baxter, Vienna, Austria).
Constructs were subcutaneously implanted in the back of
fifteen CD-1 nu/nu mice aged 6–8 weeks, purchased from
Charles River- Calco, LC, Italy. Mice were euthanized after
2 months and constructs were harvested and processed for
further analysis.
All animal experiments were approved by the regulatory
board for animal welfare of IRCCS AOU San Martino-IST Istituto
Nazionale per la Ricerca sul Cancro animal facility and Italian
Ministry of Health and were in line with European Union
guidelines.
Histology analysis
Harvested constructs were fixed in PFA 3.7%, decalcified with
Osteodec (Bio-Optica, Milano, Italy) and embedded in paraffin
using standard histological procedure. Five-micrometer serial
sections were cut. To reveal the different types of formedtissues, sections were stained with hematoxylin and eosin
(H&E) and with Goldner modified Masson's Trichrome
(Bio-Optica) to detect erythrocytes in gold yellow. Vessel
density (number of vessels with a diameter ≥ 40 μm per
section) and total perfusion area (sum of lumen areas of
vessels per section) were calculated on six 5 μm-sections on 5
samples per group using the Axiovision Rel 4.4 software and
the Axiovert 200 microscope (Zeiss).
In vivo cell tracking
To track cells in the ectopic bone, we stably infected AFSCs
with a retrovirus coding for the firefly luciferase and used an
in-vivo bioluminescence imaging technique. For the retroviral
plasmid production, the firefly luciferase gene was obtained
as a SalI/BglII fragment from pGL3-control vector (Promega),
and cloned into the XhoI/BamHI sites of the retroviral pLXIN
bicistronic vector (Clontech), (previously modified inserting
the restriction sites NotI, BglII, XhoI, ClaI, SalI, BstxI, and
BamHI into the multiple cloning site) to obtain pL-Luc-IN2. To
generate the producer cell line, the GP + env AM-12
amphotropic packaging cell line (Markowitz et al., 1988) was
transfected with 10 μg of pL-Luc-IN2 using Fugene-6 reagent
(Roche, Applied Science, Monza, Italy). The amphotropic
packaging cell line was then selected with G418 (Gibco) at
1 mg/ml (active form) for 20 days. Sixty percent confluent
human AFSCs were incubated for 18 h with 10 ml of the
packaging supernatant supplemented with 8 μg/ml of
polybrene (Sigma) and filtered through a 0.22-microm filter.
A second cycle of infection was repeated after 12 h. A
constant multiplicity of infection of 50 was maintained in all
the experiments. After 48 h, the transduced cells were
selected with G418 at 0.5 mg/ml. All the experiments
involving the use of recombinant retroviruses were done in a
BL-2 environment.
Implanted mice were intraperitoneally injected with
15 mg/ml Luciferin (Promega) and after 5 min, anesthetized
mice were placed into the imaging chamber of a IVIS-100
Xenogen-Caliper (PerkinElmer). The generated light was
detected with an exposure time of 1 minute and the images
were acquired and analyzed by Living-Image 2.5 Software.
AFSC phenotype in a pro-inflammatory condition
In order to understand how AFSCs respond to inflammatory
environments that they could encounter in vivo, we treated
150,000 AFSCs/well (6-multiwell plate) with 1 ml/well serum
free αMEM containing 100 U/ml TNFα (PeproTech, Rocky Hill,
NJ, US) overnight. Control samples were treated with the same
amount of αMEM without TNFα. Conditioned media were
collected and assayed at Luminex (X-Map Technology) with a
customized multiplex cytokine panel of analytes (Panomics,
Santa Clara, CA, US), including Fractalkine, MCP-1, IL-1α, IL-6,
IL-8, SDF-1α, and IFNγ. Results are expressed in pg/ml for each
cytokine concentration. The presence of upregulated surface
molecules was also assayed in a Cyan ADP Cytofluorimeter
(Beckman Coulter). Mouse monoclonal anti-human antibodies
used for this study were: anti-ICAM1 (clone SM89), kindly
provided by Dr Alessandro Poggi (IST-San Martino Hospital), and
anti-CD40 producing hybridomas, purchased from the American
Type Culture Collection (ATCC, Manassas, VA), followed by
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antisera (Southern Biotechnology) conjugated with phyco-
erythrin (PE) (Invitrogen). Control samples were stained
with isotype-matched irrelevant mAb (Becton Dickinson)
followed by anti-isotype specific GAM-PE.
Recruitment studies and cell retrieval
To study which host cells were recruited by human AFSCs,
Skelite® cubes were seeded with 2 × 106 AFSCs or, alternative-
ly, with the same amount of bone marrow stromal cells (BMSCs)
that our laboratory received as a participant in the Purstem
Project (EU's Seventh Framework Program). Constructs were
subcutaneously implanted in the back of 6–8 weeks old CD-1
nu/nu mice, harvested after 3 days and digested twice with
100 U/ml of Collagenase Type I and II (Biochrom) plus 0.25%
Trypsin (Gibco) for 40 min at 37 °C. Cells obtained from the
digestion were analyzed by a Cyan ADP cytofluorimeter
(Beckman-Coulter, Brea CA, USA) using monoclonal Ab against
mouse PE conjugated VEGFR2 (Rat PE conjugated anti-mouse
Flk1, BD Pharmingen), mouse APC conjugated-CD31 (clone 390
from E-bioscience, San Diego, CA, USA), and mouse
FITC-conjugated-CD14 (clone rmC5-3, BD Pharmingen).
Furthermore, immuno-histofluorescence was performed on
harvested constructs (21 days in vivo) in order to trace AFSCs and
BMSCs. Anti-HLA ABC (PE conjugated, clone DX17, BD
Pharmingen) or the related isotype control (BD Pharmingen)
were used to stain implanted human cells, after an antigen
retrieval in Tris–EDTA Buffer (10 mM Tris Base, 1 mM EDTA
Solution, pH 9.0). From Novus Biologicals, we purchased rat
monoclonal anti-mouse VEGFR2, rat monoclonal anti-mouse
PECAM1, and rabbit monoclonal anti-humanMHC class 1 (HLA-B).
To check whether human osteoblasts (OBs) remained in the
transplant, OB + AFSC constructs were explanted at 2 months
and sequentially digested in 1 mg/ml trypsin (Gibco), 5 min;
2 mg/ml Dispase (Sigma), 10 min; and 800 U/ml Collagenase
type 1 (Biochrom), 45 min, 2 times. Cells obtained from the
collagenase digestions were: i) analyzed by cytofluorimetry
for the presence of human major histocompatibility complex
class 1 (Mouse PE conjugated anti-human HLA-ABC, clone
DX17, BD Pharmingen); ii) labeled with the same antibody,
followed by anti-PE MicroBead (Miltenyi Biotec, Bergisch
Gladbach. Germany), and iii) the HLA positive fraction was
separated (indirect magnetic separation) using a Mini-MACS
apparatus (Miltenyi Biotec), plated and cultured in Iscove's
Modified Dulbecco's Medium, as described for human osteo-
genic cells. After 10 days, expanded cells were screened for
the ALP activity as described above.
Statistical analysis
Values are expressed as mean ± standard error. Statistical
differences between groups were assessed by the use of
unpaired t-test and Mann–Whitney U test. We considered a
p-value b 0.05 to be significant.
Results
Induction of osteogenic differentiation of AFSC
To induce in vitro osteogenic differentiation of AFSC, we
used the thyroxine containing medium previously describedby Guldberg's group (Peister et al., 2009), both for 2D and 3D
cultures. Moreover, we used ceramic disks (Skelite) as
osteoconductive tridimensional scaffolds to further support
the in vitro formation of a bone-like matrix. The 2D cultures
showed well defined red islets, brightly stained with alizarin
(Fig. 1A), as a result of calcium deposition over the 28 days
of culture. The activity of alkaline phosphatase, another
independent indicator of osteogenic differentiation, was
also detected (Fig. 1B). In the 3D static culture, we observed
an adherent population of AFSCs, that in one week could line
the ceramic scaffold pores (Fig. 1C) and in 4 weeks
deposited bone-like matrices (eosin stained), entrapping
few round cells, especially dense at the periphery of the
ceramic disk (Fig. 1D).
Although our in vitro results suggested that AFSC were
capable to differentiate toward an osteogenic lineage, we
were unable to observe a frank bone formation in vivo. We
tested the cells in a well established ectopic model of bone
formation, consisting of the subcutaneous implantation of
cell-ceramic scaffold constructs in nude mice for 1–3 months.
Empty scaffolds were poorly populated by host cells,
showing very loose connective tissue after 2 months
(Fig. 1E). In our positive control (osteoblast constructs)
bone formation occurred throughout the entire scaffold
(Fig. 1F). Instead, in the AFSC-seeded scaffolds, different
mesodermal-derived tissues of host origin were formed, such
as fat, muscle, loose and fibrous connective tissues, as well
as unmineralized bone-like matrices (Figs. 1G–H). As we
previously demonstrated (Mirabella et al., 2011a), since
AFSCs leave the scaffold early, before they could differen-
tiate toward any lineage (see also Fig. 2), the formation of
multiple tissues was not directly due to AFSC multipotency,
rather to their capability to recruit host progenitors.
We also examined the in vivo ectopic bone forming ability
of AFSC after in vitro osteo-induction (data not shown). Only
rarely and in few areas of the scaffold, we could observe a
matrix resembling a connective tissue matrix, but not
compact and not modular as a bone matrix and not reflecting
polarized light.In vivo behavior of AFSC: comparison with bone
marrow stromal cells
We previously investigated the in vivo fate of subcutaneously
implanted human AFSCs by tracking both fluorescent (CM-DiI
labeling) and HLA-ABC positive cells (Mirabella et al., 2011a).
We had demonstrated that after twoweeks, the AFSCs had left
the implant and that thewhole cell population recovered from
the AFSC-scaffold was ofmurine origin. Here we compared the
in vivo fate of human AFSCs with human bone marrow stromal
cells (BMSC), the most common population of cells containing
a subset of stem cells with osteogenic differentiation
capability. Immunostaining for HLA-ABC on explanted con-
structs revealed that no human AFSCs were present at
3 weeks, while the BMSC-constructs still retained human
cells, which organized a connective tissue (Fig. 2A). There-
fore, we concluded that although AFSCs express mesenchymal
markers, they were not able to be integrated into the ceramic
scaffold and to achieve an osteogenic differentiation. On the
contrary they rapidly disappeared from the implant. Looking
at AFSC implants at 3 days, we could notice that AFSCs were
Figure 1 AFSCs in vitro and in vivo differentiation. (A, B) In vitro 2D osteogenic differentiation of AFSCs: red alizarin staining
(A) and ALP activity (B); (C, D) in vitro 3D osteogenic differentiation of AFSCs: cells lining Skelite pore, 1 week after seeding (C), H&E
staining of matrices after 28 days of culture (D). (E–H) In vivo ectopic bone formation: H&E staining of acellular scaffold (E), OB
construct (F), AFSC constructs (G, H). F′ and H′ are enlarged view of F and H. d = dense connective tissue, i = inflammatory
infiltrates, a = adipose, m = muscle, l = loose connective tissue, b = bone. Magnification 100× (E–H), 200X (A–D).
544 T. Mirabella et al.located close to vessels and somewere transmigrating through
the vessel wall (Suppl. Fig. 1).
The early recruitment of vessels and circulating hema-
topoietic cells, especially from the innate immune system,
could be responsible for the rapid AFSC clearance. Indeed,
comparing AFSC- and BMSC-mediated recruitment of host
cells after 3 days from implantation, we found a significant
increment of murine CD31+, CD14+ and VEGFR2+ cells in
AFSC constructs compared to BMSC constructs (Fig. 2B).
Since CD31 and VEGFR2 are both markers of endothelial
cells and monocytes (Stockinger et al., 1990; Albelda et al.,
1991; Elsheikh et al., 2005), and CD14 is preferentially
expressed on monocytes/macrophages (Ziegler-Heitbrock
and Ulevitch, 1993), it's likely that AFSCs trigger a strong
pro-angiogenic and pro-inflammatory response in the host.AFSCs are both triggering and sensitive to
inflammatory stimuli
We previously demonstrated that AFSC conditioned medium
contains pro-angiogenic soluble factors that can attract
vessels and promote the blood re-perfusion of ischemic
tissues (Mirabella et al., 2011b, 2012). Since angiogenesis is
an essential component of inflammation and its resolution,and given that AFSCs do not remain in the implantation sites
(rather host inflammatory cells are retrieved), we investi-
gated the secretory profile of AFSC cultured in basal
condition and after TNFα stimulation. We chose TNFα
because it is a known acute phase reaction cytokine
produced primarily by activated macrophages (Old, 1985).
In the basal condition, AFSCs secreted high amounts of IL-8,
MCP-1, and SDF-1, all chemokines with an established role
in promoting angiogenesis and supporting leukocyte infil-
tration (Raman et al., 2011). After TNFα stimulation, these
chemokine concentrations were almost doubled, so that
150,000 AFSCs secreted at least 1 ng of each chemokine
(Fig. 3A). A similar increase was observed with the acute
phase mediator, IL-6. Moreover, following TNFα treatment,
the AFSCs began secreting the two cytokines, IL-1α and
IFNγ, and the chemokine fractalkine (CX3CL1) (about
200 pg) that were not produced at detectable levels in the
basal culture condition. Interestingly, after TNFα stimula-
tion, AFSCs showed an increased expression of the adhesion
molecule, ICAM-1, and the co-stimulatory molecule, CD40,
both binding to leukocyte ligands (Fig. 3B). These results
suggest that AFSCs, both in basal and inflammatory
conditions, but especially in inflammatory conditions, can
chemoattract, bind and activate innate and adaptive
immune system cells.
Figure 2 Comparison between AFSCs and BMSCs in vivo. BMSCs (upper panel) and AFSCs (lower panel)-constructs are presented in
(A) and (B). (A) H&E staining (left column) and red fluorescence for HLA-ABC, DAPI counterstained (right column) for explants at
21 days. Magnification: 400×. (B) FACS analysis for recruited VEGFR2, CD31, CD14 positive cells at 3 days. The indicated markers
(black histogram) and the isotype matched controls (grey histogram) and the percentage of positive cells beyond isotype stained cells
(black bar) are shown. Results are expressed as Log fluorescence intensity arbitrary units (a.u.) vs. number of cells and are
representative of three independent experiments. Data analysis with Summit 4.3.1 software. In (B), immunofluorescence for murine
VEGFR2 and CD31 are shown as well (BMSC construct at 3 days in the upper panel and AFSC construct at 3 days in the lower panel).
Magnification 200×. Dashed lines label the scaffold (Sc).
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AFSCs have been proposed and advantageously used for
orthotopic bone tissue repair (Dupont et al., 2010). To
investigate whether AFSCs could interact positively or
negatively in a bone-forming microenvironment, we adopted
a heterotopic bone formation model. Briefly, we seededhuman osteoblasts, in the presence or absence of human
AFSCs, onto a ceramic osteo-conductive biomaterial (Skelite).
Constructs were then subcutaneously implanted. After
2 months, both constructs (OB and OB + AFSC) gave rise to
tissue-engineered ossicles with mineralized bone (Fig. 4A).
We did not see significant differences between OB and
OB + AFSC constructs relative to bone tissue density and
Figure 3 AFSC secretory and immuno-profile after TNFα treatment. (A) Luminex results (pg/ml) of the indicated secreted proteins
(IFNγ, IL 1 α, IL 6, IL 8, MCP 1, FKN, and SDF 1α); (B) cytofluorimetric analysis for the expression of CD40 (upper panel) and ICAM-1
(lower panel). Black histograms indicate the surface molecules and grey histograms the isotype matches controls. Results are
expressed as percentage of positive cells (beyond black bar) and as mean fluorescence intensity ratios. Results are expressed as Log
fluorescence intensity arbitrary units (a.u.) vs number of cells. Data analysis with Summit 4.3.1 software. N = 3, *p-value b 0.05
between CTRL and TNFα for all analytes.
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medullary (inner part of pores) bone throughout the scaffold
surfaces (Fig. 4B). However, the pro-inflammatory reaction
that AFSCs mediated in vivo, caused increased vasculariza-
tion (Fig. 4A, red blood cells in gold yellow), without
affecting the regular formation of bone by the osteoblasts.
Vessel density and total perfused area (Figs. 4C–D) were
significantly increased in OB + AFSC constructs, meaning
that more and larger vessels infiltrated the engineered
ossicle when AFSC were in loco. We concluded that AFSC,
although not playing a direct role in new bone formation,
could drive the bone niche modeling in terms of blood
perfusion.
AFSCs are not integrated in the neo-formed
bone niche
To determine if AFSCs directly contribute to the ectopic
bone niche, we transduced AFSC with the luciferase gene
before seeding OBs and AFSCs onto Skelite cubes, and we
monitored through time the presence of AFSCs in the
construct. The luminescent signal was very bright one day
after the implantation and was dramatically decreased after
1 week. After 2 weeks AFSCs were undetectable (Fig. 5A).
Since AFSCs were not detectable in the scaffold within
2 weeks, we inferred that the only human cells directly
participating in the bone formation were the osteoblasts. In
order to confirm that osteoblasts were the only human cells
remaining in the bone engineered niche, two months afterimplantation we explanted and digested the OB + AFSC
constructs and searched for the presence of the human
marker HLA-ABC in the single cell suspension. About 10–20%
of recovered cells were of human origin (HLA-ABC positive)
(Fig. 5B). We isolated those HLA-ABC positive cells with
immune-magnetic beads. Isolated cells showed ALP activity
after 1 week of culture performed in normal (not osteogen-
ic) medium (Fig. 5C). Thus, we confirmed the presence of
osteoblasts of human origin.
Finally, when OB were mitotically inactivated with mito-
mycin C prior to their seeding onto the scaffold, only adipose
and loose tissues populated the scaffold (Fig. 6A). When AFSCs
were co-seeded with mitotically inactivated OBs, again no
bone was obtained (Fig. 6B). These data confirm that AFSCs
were neither able to differentiate to an osteoblastic pheno-
type nor rescue osteogenesis. These data also prove that
viable and proliferative osteogenic-committed cells were
necessary for the formation of the bone.Discussion
Large bone defects/injuries represent a major challenge for
orthopedic and reconstructive surgeons since both bone
auto- and allo-grafts can be used in a restricted spectrum of
cases due to limited amount of collectible tissues, immune
rejection and pathogen transmission from donor to host (Lu
et al., 2000). Bone tissue engineering is usually achieved by
combining a reliable source of stem cells, easy to isolate and
Figure 4 Ectopic bone niche formation in presence of AFSCs. (A) Planimetry (5 × 5 mm) of explanted OB construct (upper panel)
and OB + AFSC construct (lower panel) in H&E staining (on the left). Reconstruction made with 100× magnification pictures. The same
constructs (OB construct in upper image and OB + AFSC construct in lower image) are stained with Goldner modified Masson's
trichrome (on the right); gold yellow stains blood cells, green stains bone. Arrows indicate vessels. Magnification 100×; (B) bone
density as sum of bone covered areas per section on a total of 6 sections per sample; (C) vessel density as number of counted vessels
per section on a total of 6 sections per sample; (D) total perfusion area as sum of lumen areas of the vessels per section on a total of 6
sections per sample. N = 5 samples per group, *p b 0.05.
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Figure 5 Human cell tracking in the engineered bone. (A) AFSCs were transfected with the vector L-Lucin 2 (on the left) and traced
in the AFSC + OB constructs at days 1, 7, and 14 by IVIS-100 Xenogen-Caliper (PerkinElmer). Images processed by Software
Living-Image 2,5; (B) representative result of the percentage of human (HLA-ABC positive, beyond isotype ctrl stained cells indicated
with the black bar) cells recovered from OB + AFSC constructs at 2 months; (C) culture of human cells isolated from OB + AFSC
constructs: elongated and fusiform morphology the day after plating (left picture, magnification 100×) and ALP activity staining after
1 week in culture (right picture, magnification 400×).
548 T. Mirabella et al.expand, and a bone mimicking-scaffold as a temporary
matrix that supports cellular 3D growth (Salgado et al.,
2004). Bone marrow stromal cells are the most commonly
used cells to treat long bone segmental defects, but
drawbacks such as reduced availability in aged people and
cell senescence after few passages in culture (Derubeis and
Cancedda, 2004) have pushed researchers to look for other
cell sources of bone-regenerating cells. Amniotic fluid has
been described as a potential source of mesenchymal stem
cells (In 't Anker et al., 2003; Tsai et al., 2004), which can be
extensively expanded (N250 population doublings) in cul-
ture without telomere shortening (De Coppi et al., 2007).
AFSCs were demonstrated to be capable to produce robust
mineralization in vitro (Peister et al., 2011) and to promote
ectopic bone formation (De Coppi et al., 2007) and
segmental bone defect repair (Dupont et al., 2010 and
Rodrigues et al., 2012) in vivo. However, there are concerns
about the real capability of AFSCs to differentiate and
become osteoblasts in vivo, especially when implanted
without a prior in vitro osteoinduction. To our knowledge,
to date there are no publications that convincingly show the
histology of bone formed by AFSC directly implanted in vivo.Here, using an ectopic bone model system, we found that:
i) AFSCs do not contribute to bone healing by osteogenic
differentiation or osteo-integration; ii) AFSCs are not retained
in the bone microenvironment, do not affect the osteo-
synthesis, and domodel the site in terms of vascular perfusion;
iii) and AFSC in vivo clearance could be due either to the cell
intrinsic mobility or to their pro-inflammatory properties
including their capacity to recruit host myeloid cells, or both.
In our hands, AFSCs could be osteo-induced in vitro in
both 2D and 3D cultures. However, in vitro assays, although
important, are not predictive of the in vivo differentiation
capability of cells along the osteo-lineage. Instead, ectopic
implantation of tissue-engineered constructs into nude mice
is a well established model of in vivo bone formation (An and
Friedman, 1998).
Skelite, the biomaterial that we used in our experi-
ments, is considered osteoconductive to both cell attach-
ment and tissue ingrowth and it couples biomaterial
resorption with bone formation (Mastrogiacomo et al.,
2006, 2007). In agreement with our previously published
data, we observed that Skelite per se (acellular scaffold)
was not osteoinductive in the subcutaneous environment,
Figure 6 Tissue formed by mitogenic inactivated osteoblasts. (A) Schematic view of procedure and results of implanted constructs
with osteoblasts (OB) with (upper panel) or without (lower panel) pre-treatment with mitomycin C. Only proliferative OBs can form
bone in vivo. (B) Mitomycin pre-treated osteoblasts were seeded onto Skelite cubes, with (OBmito + AFSC construct) or without
(OBmito construct) AFSCs. AFSCs do not rescue osteogenesis. Two months after implantation for all the constructs showed. Goldner
modified Masson's trichrome staining for all the histology shown (bone is stained green). Magnification 100×. Image of the Skelite
scaffold in (A) was modified from Fig. 2C in “Cancedda R. et al., Biomaterials Volume 28, Issue 15, May 2007, Pages 2505–2524”.
549Amniotic fluid stem cells in a bone microenvironment: Driving host angiogenic responsewhile it was osteoconductive when seeded with osteogenic
committed cells, such as human osteoblasts. Skelite-seeded
AFSCs were populated by a variety of mesodermal progenitors
of host origin, while AFSCs were not retained in the scaffold.
Due to the implantation site and the recent demonstration
that dermal fibroblasts are a heterogeneous population
containing progenitors with different levels of differentiation
potential (Zhang et al., 2008), one could speculate that AFSCs
might activate the local subcutaneous environment, leading
to the ingrowth of fat, muscular, loose and compact tissues
into the Skelite, although a contribution from circulating cells
cannot be ruled out.
Assuming that a tissue specific environment could play an
important role in cell fate determination, we studied AFSC
behavior in an artificial bone niche made of Skelite and
osteoblasts. Again, AFSCs were not detected in the scaffold
within two weeks from the implantation. The development of
bone was not negatively affected by the presence of AFSCs,
rather osteoblasts grew and deposited bone matrix. Only in
the case of mitotic inactivated osteoblasts was bone not
established.The emerging concept here is that osteogenic-committed,
in vivo-engrafting and proliferative cells are necessary and
sufficient to engineer bone and, although AFSCs are
considered a member of the MSC “family”, the mere
expression of mesenchymal markers does not make them
an osteocommitted stem cell. Indeed, so-called mesenchy-
mal stem cells can be found in many tissues but “skeletal
stem cells” can be found only in the bone marrow (Bianco,
2011 and Sacchetti et al., 2007).
In our experimental setting the most remarkable differ-
ence between AFSCs and BMSCs was the in vivo traceability:
BMSCs persist in vivo. Other authors (Bakondi and Spees, 2010;
Olivo et al., 2008; Krebsbach et al., 1997; Kuznetsov et al.,
1997) have already shown, using a cell tracing approach, that
adult BMSCs do contribute to bone formation in ectopic
models. Another remarkable difference between the two
sources was the early recruitment of host endothelial and
myeloid cells (CD31, CD14 and VEGFR2 positive) into the
implant: AFSCs triggered a stronger angiogenic/inflammatory
response, which could be responsible for their clearance (see
also AFSC transmigration through the vessels).
550 T. Mirabella et al.It seems evident that AFSCs, not capable of lasting in vivo
longer than 1–2 weeks, cannot be a candidate for a traditional
bone tissue engineering, unless a different approach is
considered, possibly in vitro pre-differentiation (Rodrigues et
al., 2012 and Peister et al., 2011) or the selection of more
osteo-committed subpopulations. Ours, as other authors'
protocols of in vitro pre-differentiation, need to be improved
in order to obtain a frank bone formation and avoid dystrophic
calcifications in vivo.
Nevertheless, AFSCs can still be considered as candidates
for therapeutic angiogenesis protocols. In particular, in the
case of segmental bone defects, where the vascular deficiency
and the associated nutrient diffusion are limiting factors for
tissue survival and turn-over, AFSC-mediated vascularization
could facilitate the income of circulating progenitors and
trophic factors.Conclusions
Osteo-committed cells, either collected from bone resident
populations or artificially derived from other sources by
osteo-inducing protocols, are needed to establish a bone
tissue in vivo. AFSCs, which have already being used for the
treatment of large bone defects, do not participate to the
neo-bone formation. Other mechanisms, such as host progen-
itor recruitment, blood hyperperfusion, as well as others,
need to be investigated to find out how AFSCs trigger bone
repair.
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